Compare Stocks: AUTL, SRPT, BHVN, and PHVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.11 -5.8%	$1.90	$1.17 ▼ $2.58	$596.20M	2.1	2.59 million shs	2.57 million shs
BHVN Biohaven	$14.65 -6.6%	$14.87	$7.48 ▼ $18.57	$2.37B	1.28	3.02 million shs	3.31 million shs
PHVS Pharvaris	$37.84 +7.3%	$34.86	$20.65 ▼ $43.25	$2.31B	-2.33	603,152 shs	6.33 million shs
SRPT Sarepta Therapeutics	$20.94 -6.9%	$18.43	$14.68 ▼ $25.32	$2.38B	0.27	2.76 million shs	6.24 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-5.80%	-8.66%	0.00%	+42.57%	+47.55%
BHVN Biohaven	-6.64%	-6.82%	-0.16%	+31.69%	+1.06%
PHVS Pharvaris	+7.35%	+8.33%	+8.39%	+20.09%	+73.34%
SRPT Sarepta Therapeutics	-6.93%	-1.83%	+24.79%	+38.58%	+18.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.11 -5.8%	$1.90	$1.17 ▼ $2.58	$596.20M	2.1	2.59 million shs	2.57 million shs
BHVN Biohaven	$14.65 -6.6%	$14.87	$7.48 ▼ $18.57	$2.37B	1.28	3.02 million shs	3.31 million shs
PHVS Pharvaris	$37.84 +7.3%	$34.86	$20.65 ▼ $43.25	$2.31B	-2.33	603,152 shs	6.33 million shs
SRPT Sarepta Therapeutics	$20.94 -6.9%	$18.43	$14.68 ▼ $25.32	$2.38B	0.27	2.76 million shs	6.24 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-5.80%	-8.66%	0.00%	+42.57%	+47.55%
BHVN Biohaven	-6.64%	-6.82%	-0.16%	+31.69%	+1.06%
PHVS Pharvaris	+7.35%	+8.33%	+8.39%	+20.09%	+73.34%
SRPT Sarepta Therapeutics	-6.93%	-1.83%	+24.79%	+38.58%	+18.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	2.88	Moderate Buy	$10.00	373.93% Upside
BHVN Biohaven	2.59	Moderate Buy	$18.69	27.58% Upside
PHVS Pharvaris	2.86	Moderate Buy	$53.00	40.06% Upside
SRPT Sarepta Therapeutics	2.20	Hold	$25.06	19.67% Upside

Current Analyst Ratings Breakdown

Latest AUTL, SRPT, BHVN, and PHVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	PHVS Pharvaris	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$75.00
9/8/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$23.00 ➝ $19.00
9/8/2026	PHVS Pharvaris	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
9/8/2026	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$42.00
8/28/2026	BHVN Biohaven	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/28/2026	BHVN Biohaven	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
8/27/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/26/2026	BHVN Biohaven	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	BHVN Biohaven	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$30.00
8/19/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/14/2026	PHVS Pharvaris	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$60.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$75.39M	7.45	N/A	N/A	$0.67 per share	3.15
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.71 per share	N/A
SRPT Sarepta Therapeutics	$2.20B	1.01	N/A	N/A	$10.89 per share	1.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$287.53M	-$1.06	N/A	N/A	N/A	-238.66%	-178.66%	-49.34%	10/29/2026 (Estimated)
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	11.51	0.32	-13.48%	-1.60%	-0.66%	11/4/2026 (Estimated)

Latest AUTL, SRPT, BHVN, and PHVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	1.04	4.89	4.40
BHVN Biohaven	21.23	4.73	4.73
PHVS Pharvaris	N/A	11.94	11.94
SRPT Sarepta Therapeutics	0.55	4.42	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
BHVN Biohaven	88.78%
PHVS Pharvaris	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
BHVN Biohaven	13.80%
PHVS Pharvaris	N/A
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.16 million	197.76 million	Optionable
BHVN Biohaven	239	151.04 million	130.20 million	Optionable
PHVS Pharvaris	30	65.41 million	N/A	Not Optionable
SRPT Sarepta Therapeutics	1,372	105.63 million	98.34 million	Optionable

AUTL, SRPT, BHVN, and PHVS Headlines

Recent News About These Companies

Sarepta Therapeutics (SRPT) Plunges 10.3% to $20.18

September 8 at 3:08 PM | news.alphastreet.comN

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

September 8 at 2:10 PM | benzinga.com

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

September 8 at 1:47 PM | benzinga.com

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

September 8 at 1:02 PM | reuters.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down - Should You Sell?

September 8 at 10:59 AM | marketbeat.com

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

September 8 at 10:07 AM | finance.yahoo.com

Jupiter Topco LLC Takes Position in Sarepta Therapeutics, Inc. $SRPT

September 7 at 5:03 AM | marketbeat.com

The Manufacturers Life Insurance Company Makes New $927,000 Investment in Sarepta Therapeutics, Inc. $SRPT

September 6 at 4:24 AM | marketbeat.com

Sarepta Therapeutics, Inc. $SRPT Shares Sold by AXQ Capital LP

September 6 at 3:12 AM | marketbeat.com

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

September 4, 2026 | prnewswire.com

Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?

September 4, 2026 | zacks.com

Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?

September 4, 2026 | finance.yahoo.com

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

September 3, 2026 | theglobeandmail.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 6.6% - Should You Buy?

September 2, 2026 | marketbeat.com

Empowered Funds LLC Acquires Shares of 190,586 Sarepta Therapeutics, Inc. $SRPT

September 2, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

September 2, 2026 | marketbeat.com

70,233 Shares in Sarepta Therapeutics, Inc. $SRPT Purchased by Hsbc Holdings PLC

September 1, 2026 | marketbeat.com

Canada Pension Plan Investment Board Buys Shares of 70,800 Sarepta Therapeutics, Inc. $SRPT

September 1, 2026 | marketbeat.com

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

August 31, 2026 | businesswire.com

Legal & General Group Plc Takes Position in Sarepta Therapeutics, Inc. $SRPT

August 31, 2026 | marketbeat.com

Man Group plc Takes $7.16 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, SRPT, BHVN, and PHVS Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.11 -0.13 (-5.80%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$2.16 +0.05 (+2.42%)

As of 09/8/2026 07:56 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Biohaven NYSE:BHVN

$14.65 -1.04 (-6.64%)

Closing price 09/8/2026 03:59 PM Eastern

Extended Trading

$14.86 +0.22 (+1.47%)

As of 09/8/2026 08:00 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Pharvaris NASDAQ:PHVS

$37.84 +2.59 (+7.35%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$37.91 +0.07 (+0.18%)

As of 09/8/2026 07:57 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Sarepta Therapeutics NASDAQ:SRPT

$20.94 -1.56 (-6.93%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$21.10 +0.16 (+0.78%)

As of 09/8/2026 07:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUTL, SRPT, BHVN, and PHVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUTL, SRPT, BHVN, and PHVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUTL, SRPT, BHVN, and PHVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, SRPT, BHVN, and PHVS Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Biohaven NYSE:BHVN

Pharvaris NASDAQ:PHVS

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUTL, SRPT, BHVN, and PHVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUTL, SRPT, BHVN, and PHVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUTL, SRPT, BHVN, and PHVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, SRPT, BHVN, and PHVS Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Biohaven NYSE:BHVN

Pharvaris NASDAQ:PHVS

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools